For The Better

This is a classic matchup of a grizzled top dog against a scrappy competitor.

Buying pharmaceutical companies with all-around drug portfolios and pipelines is the key to success as an investor.

Clorox’s margins got crushed as inflation spiked. Management said they were working on it. Here’s the proof.

This company tells a nice story, but it’s fighting an uphill battle.

These two stocks have decades of consistent dividend raises between them.

The social media company beat analyst expectations and is hiring to grow its artificial intelligence capabilities.

2023 started in top form, but investors took issue with the outlook.

Tesla has long enjoyed a margin advantage over competitors.

The gene-sequencing company reported weaker results while the Federal Trade Commission has ordered it to divest its Grail acquisition.

Disney and Costco both have an edge.

Cybersecurity is a recession-proof industry.

The company sees a long-term demand tailwind coming from AI.

There is a lot for investors to like about these dividend giants.

Banks experienced significant funding pressure in the first quarter of the year.

Benefit cuts are unfortunately on the table, but that doesn’t mean you’re totally doomed.

Coinbase is taking its fate into its own hands.

These two stocks should make value investors crack a smile.

Brendan Ballou, author of “Plunder: Private Equity’s Plan to Pillage America,” pulls back the curtain.

The Las Vegas giants have some major differences in their businesses.

The take rate is the story of the first quarter.